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Purpose: To examine the intraocular distribution of bevacizumab at four weeks after intravitreal bevacizumab (IVB)
injection and to investigate the effects of IVB on apelin and vascular endothelial growth factor (VEGF) in the central
retinal vein occlusion (CRVO) of monkey eyes.
Methods: Direct laser coagulation was performed on all branch retinal veins in the right eyes of six Rhesus monkeys to
establish a CRVO model. The eyes of the first three monkeys were enucleated one week, two weeks, and 24 weeks after
the establishment of the CRVO model; this was the CRVO group. Subsequently, IVB was injected into the eyes of the
last three monkeys one week, two weeks, and 24 weeks after laser coagulation; this was the IVB group. The left eye of
the first monkey was used as normal control. Immunohistochemistry and reverse-transcription PCR was used to examine
the expression of apelin and VEGF. The penetration of bevacizumab into the retina and iris was investigated by
fluorescence immunostaining.
Results: Immunoreactivity for bevacizumab could be detected in the vessel walls of the iris and choroid on day 28 after
injecting IVB: apelin and VEGF staining had been more prominent than normal in the CRVO eye, but these decreased
following IVB injection. Expression of apelin mRNA (p<0.01) was lower in the IVB group than the CRVO group and
did not vary significantly between groups.
Conclusions: Bevacizumab could be detected in the iris and choroid after four weeks of intravitreal injection. Apelin may
be partially suppressed by bevacizumab, and it may play a role in retinal neovascularization during the development of
CRVO.
Central retinal vein occlusion (CRVO) is one of the most
common retinal vascular diseases involving blindness [1].
Macular  edema,  caused  by  a  decline  in  the  blood–retina
barrier, contributes to central vision loss. The decreased tissue
perfusion leads to possible neovascular complications, such
as  rubeosis  iridis  and  neovascular  glaucoma,  which  can
severely  influence  quality  of  life  [2,3].  At  present,
photocoagulation has been widely used in CRVO to prevent
neovascular  complications.  However,  it  cannot  improve
vision  prognosis.  Some  evidence  suggests  that  repeated
intravitreal injections of triamcinolone may improve vision,
but  the  complication  of  intraocular  pressure  and  cataract
makes it a less than ideal treatment [4].
The pathogenesis of CRVO is not very well understood
and remains controversial. However, it is widely accepted that
vascular endothelial growth factor (VEGF) plays an important
role  in  CRVO  development  [5].  Anti-VEGF  therapy,
including intravitreal bevacizumab (IVB), has proven to be
Correspondence  to:  Yan-Rong  Jiang,  Department  of
Ophthalmology, People’s Hospital, Peking University, 11 Xizhimen
South  Street,  Xicheng  District,  Beijing  100044,  China;  Phone:
86-10-88325413;  FAX:  86-10-88395310;  email:
drjyr@vip.sina.com
effective  in  improving  visual  acuity  and  inhibiting
neovascularization [6,7]. However, research has revealed that
anti-VEGF alone cannot completely prevent the occurrence
of new vessels, which indicates that other factors may also
participate in the process of neovascularization apart from
VEGF [8]. Apelin is reported to act as an angiogenic factor
that could stimulate the proliferation and migration of retinal
endothelial cells and vascular tube formation [9,10]. That
function cannot be replaced by VEGF [11]. Besides, recent
studies  suggest  that  apelin  may  be  involved  in  retinal
neovascularization during the development of proliferative
diabetic  retinopathy  [12].  In  an  eye  with  CRVO,
hypoperfusion causes stasis of the retinal bloodstream and
retinal  tissue  hypoxia,  which  may  induce  upregulation  of
apelin, thereby simulating neovascularization.
To  evaluate  the  potential  effect  of  apelin  in  the
pathogenesis of CRVO, we conducted the present study to
examine whether bevacizumab could be detected four weeks
after IVB and to investigate the expression of apelin in eyes
with  central  retinal  vein  occlusion  and  the  effect  of
bevacizumab.
METHODS
Establishment of CRVO model: We established the CRVO
model by obstructing all major retinal branch veins (usually
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1044two to three veins) of single eyes in six rhesus monkeys. All
investigation involving animals conformed to the guidelines
of  the  Association  for  Research  in  Vision  and
Ophthalmology's  Resolution  Statement  for  the  Use  of
Animals in Ophthalmic and Vision Research. The veins were
obstructed completely and permanently by mean of a green
argon laser (Novus Omni system; Coherent Lambda Physik,
Dieburg, Germany) with energy of 400–500 mW. Among the
six eyes, five eyes received a second laser photocoagulation.
Grouping of animals: Animals were numbered No. 1 to No.
6 and divided into different groups, as shown in Table 1. The
left eye of No. 1 was used as the normal control. The right
eyes of No. 1, 2, and 3 were enucleated one week, two weeks,
and 24 weeks after the establishment of the CRVO model.
These were used as the CRVO group and named “1 w,” “2
w,” and “24 w,” respectively, The right eyes of No. 4, 5, and
6,  which  were  enucleated  four  weeks  after  intravitreal
injection of bevacizumab, were defined as the IVB group and
named  “1  w+IVB,”  “2  w+IVB,”  and  “24  w+IVB,”
respectively. In the IVB group, No. 4, 5, and 6 differed in the
intervals between the establishment of the CRVO model and
intravitreous injection of bevacizumab, which were one week,
two weeks, and 24 weeks, respectively.
Intravitreal  injection  of  bevacizumab:  Bevacizumab
(Avastin; Roche, San Francisco, CA) with dosage of 0.05 ml
(1.25 mg) was injected into the vitreous cavity under sterile
conditions. Before injection, an anterior chamber puncture
was  made  to  maintain  normal  intraocular  pressure.  The
animals were anesthetized with intramuscular injection of
30  mg/kg  bodyweight  ketamine  hydrochloride  (Ketalar,
Parke-Davis, Morris Plains, NJ). Routine ocular examinations
were done immediately after injection, in case of retina or lens
injury.  Levofloxacin  Eye  Drops  (Santen  Pharmaceutical
Co.,Ltd., Ishikawa,Japan) were administered from this time
point four times a day for 4 days to prevent infection. Animals
were monitored for signs of inflammation until euthanasia
with  intramuscular  injection  of  10  mg/kg  ketamine
hydrochloride  (Ketalar,  Parke-Davis)  followed  by
intravenous 100 mg/kg pentobarbital sodium (Sigma-Aldrich,
St. Louis, MO).
Fluorescence immunostaining: Eyes were enucleated, fixed
in  formalin,  embedded  in  paraffin  wax,  sectioned,  and
deparaffinized.  Goat  fluoresceinisothiocyanate-conjugated
anti-human  immunoglobulin  G  (IgG;  Zhongshan
Goldenbridge Biotechnology, Beijing, China) was used to
detect  bevacizumab  at  a  dilution  of  1:50.  Following
incubation, the slides were washed and stained with 4’,6’-
diamino-2-phenylindole (DAPI, No. D9542; Sigma-Aldrich,
St. Louis, MO) at a dilution of 1:1000). The slides were
examined  with  a  fluorescence  microscope  (DS-Ril-U2;
Nikon, Tokyo, Japan), and images were acquired with a digital
camera (DS-U2, Nikon).
Hematoxylin and eosin staining and immunohistochemistry:
Routine  hematoxylin  and  eosin  (H&E)  staining  was
performed. Immunohistochemistry was performed with rabbit
anti-apelin  polyclonal  IgG  (No.  ab59469;  Abcam,
Cambridge, MA) at a dilution of 1:200 or mouse anti-VEGF
polyclonal  IgG  (No.  sc-7269;  Santa  Cruz  Biotechnology,
Santa Cruz, CA) at a dilution of 1:100. Biotin-conjugated goat
antirabbit  IgG,  or  biotin-conjugated  goat  antimouse IgG
(Zhongshan  Goldenbridge  Biotechnology)  were  used  as
second antibodies, followed by DAB imaging. Photographs
TABLE 1. GROUPING OF ANIMALS
Number Eye Time (w) Group Group name Description
1 OS - Control Normal -
1 OD 1* CRVO 1 w Photocoagulation
2 OD 2*   2 w Photocoagulation
3 OD 24*   24 w Photocoagulation
4 OD 4** IVB 1 w + IVB IVB at 1 week after photocoagulation
5 OD 4**   2 w + IVB IVB at 2 weeks after photocoagulation
6 OD 4**   24 w + IVB IVB at 24 weeks after photocoagulation
        * represents the time (weeks) between creation of retinal vein occlusion and the enucleation. ** represents the time (weeks)
        between intravitreal injection of bevacizumab and the enucleation.
TABLE 2. THE SPECIFIC PRIMERS.
Name Primers (5′-3′) Product length
human apelin F: CACCTCGCACCTGCTGTA 119 bp
  R: GAACGGGAATCATCCAAAC  
human vascular endothelial growth factor F: TCCCCCTTGGGATCCCGCAG 91 bp
  R: GGCCGGGGAGGAGGTGGTAG  
Glyceraldehydes 3-phosphate dehydrogenase F: GAGTCCACTGGCGTCTTCAC 120 bp
  R: GTTCACACCCATGACGAACA  
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1045were acquired using a digital camera (DS-U2; Nikon) with the
same camera settings (brightness, contrast, etc.)
Detection  of  mRNA  by  reverse-transcription  PCR:  The
embedded retinal tissue was sectioned, deparaffinized, and
digested in proteinase-K (P6556; Sigma-Aldrich, St. Louis,
MO). Total RNA was extracted from the retinal tissues of all
groups. Two micrograms of RNA were converted into cDNA
in  a  total  reaction  volume  of  25  µl,  and  the  reverse
transcription product (1 µl) was then amplified by reverse-
transcription PCR. The specific primers of human VEGF,
human  apelin  and  glyceraldehyde  3-phosphate
dehydrogenase  (GAPDH)  were  listed  in  Table  2.  PCR
products were electrophoretically separated on 2% agarose
gel  in  a  1×  tris-borate-  EDTA  (TBE)  buffer.  The  optical
density  of  each  band  was  determined  using  BandScan
software 4.5 (Glyko, Inc., Hayward, CA). For each band, five
values were generated following the same procedure. The
densitometric values for apelin and VEGF were normalized
using GAPDH levels.
Figure 1. Photographs of fundus. A: This shows the normal fundus. B: Central retinal vein occlusion (CRVO) model was successfully
established by photocoagulation. The fundus photograph shows photocoagulation spots and dilated retinal veins at the first day after
photocoagulation.
Figure 2. Hematoxylin and eosin staining section. With the establishment of central retinal vein occlusion (CRVO) model, the pathological
changes of retina were remarkable. A: This image shows the normal retina structure. B: This image shows interstitial edema of the retina 7
days after photocoagulation. C: This image shows disordered retinal structure 24 weeks after photocoagulation.
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1046Statistical analyses: The statistical analysis was performed
using a commercially available statistical software package
(Statistical Package for Social Sciences for Windows, version
17.0; SPSS, Chicago, IL). Tests for independent samples were
performed to compare differences in densitometric values for
apelin or VEGF. Two-tailed probabilities of less than 0.05
were considered to indicate statistical significance.
RESULTS
Establishment of the central retinal vein occlusion model: The
CRVO model was successfully established. On the first day
after  photocoagulation,  fundus  photograph  showed  laser
photocoagulation spots and dilated retinal veins (Figure 1B),
compared to normal fundus (Figure 1A).
A normal H&E section is shown in Figure 2A. Acute
retinal edema was remarkable at 7 days after photocoagulation
(Figure 2B). Disordered retinal structure was observed 24
weeks after the establishment of the CRVO model (Figure
2C).
Fluorescence immunostaining of bevacizumab: In the IVB
group,  bevacizumab  was  detected  in  the  iris  and  choroid
vessels (Figure 3) of all eyes at four weeks after intravitreous
injection. There was no obvious difference among the three
groups of “1 w+IVB,” “2 w+IVB” and “24 w+IVB.”
Immunohistochemistry of vascular endothelial growth factor:
In normal monkey eyes, VEGF was detected in retinal vessel
walls  (Figure  4).  In  the  iris  tissue,  there  was  no  positive
finding.
As to CRVO groups, VEGF was detected in retinal vessel
walls  (Figure  5A-C).  By  contrast,  there  was  no  obvious
positive staining in the IVB groups. In group “24 w+IVB,” in
addition  to  VEGF-positive  staining,  disordered  retinal
structure and increased vessels were found. In the iris, VEGF
was also detected in CRVO groups, and the amount of vessels
increased with the prolongation of the course of the disease
(Figure 6A-C). In the IVB group, VEGF could not be detected
(Figure 6D-E).
Figure 3. Fluorescence immunostaining
of  eye  tissues  after  inravitreal
bevacizumab  (IVB)  injection.  4’,6’-
diamino-2-phenylindole  (blue)  was
used  to  show  nuclei  and  positive
staining  of  bevacizumab  (green)  was
showed  in  blood  vessels.  A:
Bevacizumab  (green)  was  detected  in
choroid vessels four weeks after IVB.
B: Bevacizumab (green) was detected in
the walls of iris vessel four weeks after
IVB.
Molecular Vision 2011; 17:1044-1055 <http://www.molvis.org/molvis/v17/a117> © 2011 Molecular Vision
1047Immunohistochemistry of apelin: Similar to VEGF, apelin
was detected in normal retinal vessel walls but not in the iris
(Figure 4). Apelin-positive staining was seen in the retinal
inner nuclear layer, outer nuclear layer, and ganglion cells
(Figure 7A-C), apart from the vessel walls. The prolongation
of the course of the disease seemed to have nothing to do with
apelin staining. In the IVB groups, decreased apelin staining
was observed, and the distribution was similar to that of the
normal eyes, except for the “24w+IVB” group (Figure 7D-E).
Apelin was stained in the iris blood vessels, and expression
was down-regulated after IVB injection (Figure 8).
Expression of mRNA of vascular endothelial growth factor
and apelin: The results of the PCR from the retinal tissue of
each group are shown in Figure 9A. Expression of VEGF and
apelin mRNA was observed in the normal monkey eye. In all
stages for the CRVO groups, the expression of VEGF mRNA
was upregulated, compared to the normal group (p<0.01). In
the “24 w” group, the expression of VEGF mRNA was lower
than in the “1 w” and “2 w” groups, but still higher than normal
(p<0.01). After IVB, VEGF mRNA of all the three CRVO
groups  decreased  significantly  (all  p<0.01);  however,  the
VEGF mRNA level did not vary significantly between “1w
+IVB” group, “2w+IVB” group and “24w+IVB” group and
normal control (p=0.71, 0.12, and 0.24, respectively; Figure
9B). The expression of apelin mRNA in the CRVO group was
significantly higher than in the normal eyes (p<0.01). In the
IVB group, the expression of apelin mRNA was lower than in
the CRVO group (p<0.01), but was still higher than normal
(p<0.01; Figure 9C).
DISCUSSION
Previous  studies  have  indicated  that  bevacizumab  can
penetrate quickly into all layers of the retina and iris after
intravitreal injection [13,14]. Some researchers revealed that
bevacizumab could be detected two weeks after intravitreal
injection [15,16]. In this study, it was found that bevacizumab
was stained in choroid vessels and iris vessel walls four weeks
after  intravitreal  injection.  This  result  confirmed  the
accumulation  location  of  bevacizumab,  consistent  with
previous  studies,  and  prolonged  the  recognized  time  of
bevacizumab immunoactivity after intravitreal injection. We
speculate  that  gelatinous  vitreous  functions  as  a  kind  of
sustained release system for the diffusion of bevacizumab. On
the other hand, disturbed circulation in local blood vessels and
slow perfusion may also contribute to the accumulation of
bevacizumab in some vessels [14]. Further research about the
distribution  of  bevacizumab  in  different  diseases  will  be
helpful in determining the optimum interval between repeated
intravitreal injections of bevacizumab.
The results of immunochemistry indicated that VEGF
was  down-regulated  after  intravitreal  injection  of
bevacizumab,  which  agreed  with  previous  reports  that
intravitreal bevacizumab lowered the concentration of VEGF
in  aqueous  fluid  and  vitreous  [17-19].  However,  research
findings  have  varied  on  the  effects  of  bevacizumab  on
VEGF  mRNA  expression  [20,21].  We  found  that  the
expression  of  VEGF  mRNA  decreased  four  weeks  after
intravitreal injection of bevacizumab. These results suggest
bevacizumab improves the ischemic state and subsequently
lowers  the  secretion-inducing  pressure  of  VEGF.  The
upregulation of VEGF mRNA immediately after intravitreal
injection is supposedly related to feedback regulation, due to
the sharp drop in VEGF concentration from bonding with
bevacizumab.
Apelin was first extracted in 1998 [9]. It has been reported
to  stimulate  the  proliferation  and  migration  of  retinal
Figure 4. Immunochemistry of a normal monkey eye. Sections from normal retina and iris were examined by immunohistochemistry with
anti-vascular endothelial growth factor (VEGF) antibody and anti-apelin antibody. A: Positive staining (brown) of VEGF was showed in the
retinal vessel walls. B: Positive staining (brown) of apelin was showed in the retinal vessel walls. C: There was no positive staining of VEGF
in the section of iris. D: There was no positive staining of apelin in the section of iris.
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1048endothelial  cells,  as  well  as  to  promote  vascular  tube
formation  [10].  Research  implies  that  apelin  might  also
participate  in  regulating  new  blood  vessel  growth  in
embryonic  angiogenesis  and  tumor  growth  [11,22-24].  A
study on the role of apelin in diabetic retinopathy showed there
was  a  high  vitreous  concentration  of  apelin  in  eyes  with
proliferative  diabetic  retinopathy,  as  shown  by
immunofluorescence staining of apelin in the endothelial cells
of the fibrovascular membranes of patients with proliferative
diabetic retinopathy [12]. The above findings indicate that
apelin might be an angiogenic factor that plays an important
role in the pathogenesis of vascular disease, including retinal
vein occlusion.
Figure 5. Immunochemistry of vascular endothelial growth factor in a retina. Sections of retina were examined by immunohistochemistry
with anti-vascular endothelial growth factor (VEGF) antibody. Positive staining (brown) of VEGF was detected in retinal vessel walls in the
central retinal vein occlusion groups (A: group “1 w,” B: group “2 w,” C: group “24 w”). There was no obvious positive staining after
intravitreal bevacizumab (IVB) injection (D: group “1 w+IVB,” E: group “2 w+IVB,” F: group “24 w+IVB”).
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1049Our results also showed that apelin was expressed in the
vascular system, which was consistent with previous studies
[12]. It was further found that in the CRVO eyes, apelin was
also stained in the inner and outer nuclear layers. It has been
speculated that the cells of the inner and outer nuclear layers,
apart from vascular endothelial cells stimulated by hypoxia,
secrete apelin in the manner of autocrine and paracrine [11].
Apelin sequentially affected the endothelial cells, promoting
angiogenesis and proliferation. Apelin may play an important
role in the development of CRVO. We observed that after
intravitreal  injection  of  bevacizumab,  1)  apelin  staining
decreased, 2) the expression of apelin mRNA was down-
regulated, and 3) the down-regulation did not return to normal
levels, indicating that apelin expression may be suppressed by
Figure 6. Immunochemistry of vascular endothelial growth factor in an iris. Sections of iris were examined by immunohistochemistry with
anti-vascular endothelial growth factor (VEGF) antibody. Positive staining (brown) of VEGF was detected in vessel walls of iris in the central
retinal vein occlusion groups (A: group “1 w,” B: group “2 w,” C: group “24 w”). There was no obvious positive staining after intravitreal
bevacizumab (IVB) injection (D: group “1 w+IVB,” E: group “2 w+IVB,” F: group “24 w+IVB”).
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1050anti-VEGF  therapy;  but  the  extent  of  suppression  is  not
parallel with that of VEGF. Apelin may be partially regulated
with VEGF, to some extent. At the same time, apelin has an
independent,  upstream  signaling  pathway.  It  was  also
observed that apelin was still detected in the inner and outer
nuclear layers in the “24 w” group, instead of in the “1 w” or
“2 w” groups. We speculate that in the earlier stage, the effect
of hypoxia on the cells of the inner and outer nuclear layers is
reversible, and can be eliminated when anti-VEGF therapy
improves hypoxia. In late-stage CRVO, cells of the inner and
outer  nuclear  layers  are  irreversibly  injured,  and  begin
releasing apelin persistently.
Figure 7. Immunochemistry of apelin in a retina. Sections of retina were examined by immunohistochemistry with anti-apelin antibody.
Positive staining (brown) of apelin was detected in the retinal vessel walls, inner nuclear layer, and outer nuclear layer in the central retinal
vein occlusion groups (A: group “1 w,” B: group “2 w,” C: group “24 w”). Among the intravitreal bevacizumab (IVB) groups (D: group “1
w+IVB,” E: group “2 w+IVB,” F: group “24 w+IVB”), only “24 w+IVB” group had positive staining of apelin in nuclear layers.
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1051There remain some potential limitations in our study.
First, this is a preliminary study. Due to the small number of
animals  and  lack  of  fresh  tissue,  some  tests  were  not
performed,  such  as  western  blotting,  which  would  have
provided more-accurate quantitative evidence. Second, rhesus
monkeys were used as the experimental model. We cannot
exclude  the  possibility  that  the  humanized  antibody
bevacizumab  interfered  with  the  monkey’s  immunology.
More  evidence  needs  to  be  produced  to  translate  these
conclusions from monkey to humans. Third, the investigation
of the interaction between apelin and VEGF did not involve
the molecular signaling level. Our deductions lack sufficient
experimental support. In addition, previous studies revealed
that apelin mainly promoted the growth of immature vessels.
Figure 8. Immunochemistry of apelin in an iris. Sections of iris were examined by immunohistochemistry with anti-apelin antibody. Positive
staining (brown) of apelin was detected in iris vessel walls in the central retinal vein occlusion groups (A: group “1 w,” B: group “2 w,” C:
group “24 w”), and there was no obvious positive staining in the intravitreal bevacizumab (IVB) groups (D: group “1 w+IVB,” E: group “2
w+IVB,” F: group “24 w+IVB”).
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1052A study on the earlier acute stage of CRVO may be necessary
and important.
In conclusion, bevacizumab could be detected after four
weeks  of  intravitreal  injection.  Apelin  staining  was
prominent,  and  the  expression  of  apelin  mRNA  was
significantly higher in the CRVO group. Intravitreal injection
of  bevacizumab  down-regulated  the  expression  of  apelin
mRNA, to some extent. These results suggest that apelin may
play a role in the development of CRVO, and that apelin has
a  unique  upstream  signaling  pathway,  independent  of  the
VEGF pathway.
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